T he introduction of the potent and rapidly acting antimalarial drug artesunate has been a significant advance in the treatment of severe malaria, decreasing the case fatality rate in adult severe malaria by 35% compared with quinine (1). By contrast, of the many other interventions tried, none have been shown to lower mortality.
Severe falciparum malaria has been associated with an increase in oxidative stress, in relation with disease severity (2) (3) (4) . Possible origins of reactive oxygen species are malaria parasites or host white cells (3) (4) (5) (6) . Although reactive oxygen species may be important for parasite clearance (2) , they may be harmful to the host through its damaging effects on various cells and a reduction in erythrocyte deformability (7) . Rigidity of erythrocytes reduces their lifespan and is thought to contribute to impaired microcirculatory flow, in addition to sequestration of parasitized erythrocytes (8) . Severity of anemia correlates with measures of oxidative damage to the erythrocyte membrane in pediatric severe malaria (9) .
N-acetylcysteine (NAC) is a widely used, safe, and well-tolerated antioxidant. It is the main treatment for acute parac-etamol poisoning, acting through direct scavenging of free radicals and replenishment of glutathione and cysteine. It also enhances clearance of peroxides through glutathione peroxidase and related enzymes. NAC has also been shown to improve microcirculatory blood flow in acute liver failure (10) . NAC may be beneficial in severe malaria through enhancing scavenging of free radicals and reducing expression of endothelial ligands (11) . Red cell deformability can be improved by NAC in an in vitro test system (12) . A pilot study in Western Thailand showed that intravenous NAC was associated with a significantly shorter time to normalization of plasma lactate and Glasgow Coma Score (GCS) in patients with malaria treated with quinine (13) . Another study in Thailand confirmed the safety of NAC as an adjunctive treatment to artesunate in severe malaria (14) . However, NAC was shown to partly antagonize the antimalarial action of artesunate in vitro (15) . The antimalarial effect of the artemisinin derivatives depends on the unique endoperoxide bridge Objective: Markers of oxidative stress are reported to be increased in severe malaria. It has been suggested that the antioxidant N-acetylcysteine (NAC) may be beneficial in treatment. We studied the efficacy and safety of parenteral NAC as an adjunct to artesunate treatment of severe falciparum malaria.
Design: A randomized, double-blind, placebo-controlled trial on the use of high-dose intravenous NAC as adjunctive treatment to artesunate.
Setting: A provincial hospital in Western Thailand and a tertiary referral hospital in Chittagong, Bangladesh.
Patients: One hundred eight adult patients with severe falciparum malaria.
Interventions: Patients were randomized to receive NAC or placebo as an adjunctive treatment to intravenous artesunate.
Measurements and Main Results: A total of 56 patients were treated with NAC and 52 received placebo. NAC had no significant effect on mortality, lactate clearance times (p ‫؍‬ 0.74), or coma recovery times (p ‫؍‬ 0.46). Parasite clearance time was increased from 30 hours (range, 6 -144 hours) to 36 hours (range, 6 -120 hours) (p ‫؍‬ 0.03), but this could be explained by differences in admission parasitemia. Urinary F 2 -isoprostane metabolites, measured as a marker of oxidative stress, were increased in severe malaria compared with patients with uncomplicated malaria and healthy volunteers. Admission red cell rigidity correlated with mortality, but did not improve with NAC.
Conclusion: Systemic oxidative stress is increased in severe malaria. Treatment with NAC had no effect on outcome in patients with severe falciparum malaria in this setting. (Crit Care Med 2009; 37:516 -522) KEY WORDS: N-acetylcysteine; severe malaria; adjunctive treatment within the 1,2,4-trioxane nucleus, and is mediated by the formation of free radicals upon cleavage of the endoperoxide (16) .
We hypothesized that NAC, as an antioxidant adjunctive treatment, can decrease harmful oxidative stress in severe malaria, and can have a beneficial effect on outcome parameters related to prognosis. We conducted a randomized, double-blind, placebo-controlled clinical trial, on the effect of NAC as an adjunctive treatment to artesunate in adult patients with severe falciparum malaria. Primary end points were the effects on lactate clearance time, coma recovery time, and parasite clearance time. Adults patients (Ն16 years old) with slideconfirmed severe malaria according to modified World Health Organization criteria (19) were recruited, provided written informed consent was obtained from the attending relative. Criteria for severe malaria included coma (GCS Ͻ11), acute respiratory distress syndrome, repeated convulsions, severe anemia or jaundice (hematocrit Ͻ20%, bilirubin Ͼ3.0 mg/dL, combined with parasite counts Ͼ100,000/uL), renal failure (serum creatinine Ͼ3 mg/dL), hypoglycemia (blood glucose Ͻ40 mg/dL), shock (systolic blood pressure Ͻ80 mm Hg with cool extremities), hyperparasitemia (peripheral asexual stage parasitemia Ͼ10%), hyperlactatemia (venous plasma lactate Ͼ4 mmol/L), or acidemia (venous plasma bicarbonate Ͻ15 mmol/L). Pregnancy, breast feeding, a history suggesting asthma or hypersensitivity to NAC, a wheeze on auscultation at admission, or previous treatment with lactate containing intravenous fluids were exclusion criteria.
PATIENTS AND METHODS
Since plasma lactate concentrations have a strong prognostic significance in severe malaria (20), we powered the study to demonstrate an increase in the proportion of patients with venous plasma lactate levels Ͻ2 mmol/L at 24 hours from 20% to 50% with a significance level (␣) of 0.05 and a power (1-␤) of 0.80. On the basis of this, we required at least 90 patients in the study. The primary end point was chosen to inform the decision whether to expand to a larger trial with mortality as end point.
Drug Treatment. Patients were randomly assigned to either NAC or matching placebo as an adjunctive treatment to parenteral artesunate (Guilin No. 2 Pharmaceutical Factory, Guangxi, People's Republic of China). Computerized randomization was balanced in blocks of 40, and allocation codes were kept in sealed envelopes. Patients, physicians, and nurses were masked to the treatment assigned. NAC was obtained as 10 mL ampoules containing 20% w/v NAC from Medeva, Celltech Group, Berkshire, UK, who also supplied matching ampoules containing placebo. NAC was given intravenously in the standard regime used in paracetamol intoxication, i.e., 150 mg/kg in 200 mL 5% dextrose water (5% DW) over 15 minutes, followed by 50 mg/kg in 500 mL 5% DW over 4 hours, then 100 mg/kg in 1000 mL 5% DW over 16 hours. Since NAC has a distinctive odor, treating doctors were not involved in the preparation of the infusion. The saline placebo was given in 5% DW. The first dose of NAC or placebo was started 2 hours after starting intravenous artesunate. The standard dosing regimen for artesunate was used (1) . Supportive treatments were in accordance with World Health Organization (21) and local hospital guidelines, but availability of renal replacement therapy and mechanical ventilation was limited in the hospital in Chittagong.
Study Procedures. At admission, a full history and examination were carried out. Venous blood samples were obtained for hemoglobin, hematocrit, parasitemia, platelet count, white cell count, plasma lactate levels, glucose levels, and full biochemistry. Parasite counts and lactate levels were assessed every 6 hours. Red cell deformability was measured at a shear stress of 1.7 Pa at admission, 6 hours after admission, and then daily until discharge using a Laser-assisted Optical Rotational Cell Analyzer (8) . Lactate concentrations were measured from stored plasma samples (Ϫ30°C) with YSI 2300 STAT PLUS glucose/Llactate version 250D. Urine F 2 -isoprostane metabolites (F 2 -isoP-M) levels were used as a measure of oxidative stress and assayed at admission and daily until discharge or death. Urine was collected from the urinary catheter and stored without preservative at Ϫ80°C or in liquid nitrogen. Urinary concentration of F 2 -isoP-M was measured using a highperformance liquid chromatography method coupled to electrospray ionization-tandem mass spectrometry. The urinary content of F 2 -isoprostanes metabolites was corrected for renal function by calculating the ratio with creatinine clearance with the formula (22, 23):
Excretion of prostanoids (like F 2 -isoP-M) is decreased in parallel with creatinine clearance, as shown in patients with liver disease (24). Vital signs, oxygen saturation, conscious level (GCS), fluid input, and output were recorded 6 hourly until recovery. Parasite clearance time was defined as the interval between start of treatment and the first of two sequential negative thick films. PC50 is the time to 50% and PC90 to 90% reduction in parasite density. Parasite reduction ratios at 24 hours (PRR24) and 48 hours (PRR48) were defined as the ratio of the parasite count at admission to that at 24 or 48 hours (25). Fever clearance time was the time to a tympanic measured temperature below 37.5°C. Coma recovery time was measured from the start of antimalarial treatment to the time the GCS score reached 15. Time to normal plasma lactate level was the time to a decrease in plasma concentrations Ͻ2 mmol/L (upper limit of normal value). Follow-up for all patients was from admission until discharge or death.
Primary outcome measures were lactate clearance time, coma recovery time, and parasite clearance time. Secondary outcome measures included fever clearance time, mortality, other parasite clearance measures (PC50, PC90, PRR24, and PRR48), change in red cell deformability and measures of oxidative stress, and the frequency of adverse events.
Statistical Analysis. Analysis was performed by SPSS software (version 11.0) (Chicago, IL) and STATA (version 9, College Station, TX). Data were log transformed to obtain a normal distribution, if indicated. Normally distributed data were compared using Student's t test and non-normally distributed data were compared using Student's t test for geometric means or the Mann-Whitney U test for nonpaired nonparametric data or the Wilcoxon's signed-rank test for paired nonparametric data. Categorical data were compared by Pearson's chi-squared test and Fisher's exact test. Multiple groups were compared by analysis of variance, and comparisons between individual groups were corrected for multiple comparisons (Bonferroni). Univariate correlations were checked with Pearson's correlation coefficient if the data were normally distributed or could be transformed to a normal distribution. Kaplan-Meier plots were constructed for timedependent parameters. For comparison between treatment groups (Wilcoxon-Breslow test), the lactate clearance times and coma recovery times in patients who died before clearance or recovery were set as infinite, since failure to clear lactate or recover from coma has strong prognostic significance for death. To assess whether treatment had any effect on the time to lactate or parasite clearance and coma recovery times, Cox regression analysis was performed, while adjusting for (log) initial parasitemia and bilirubin, since these were significantly different between the two groups at baseline. To determine whether treatment was associated with the risk of dying, a multiple logistic regression analysis was performed with mortality as the dependent variable and allocation to NAC or placebo as the independent variable. The model was also adjusted for presenting severity symptoms.
RESULTS
Hundred eight patients were enrolled in the study, 23 in Mae Sot General Hospital and 85 in Chittagong Medical College Hospital. Of these, 56 patients (13 at Mae Sot) were randomized to receive NAC and 52 (10 at Mae Sot) received placebo.
Baseline Characteristics. Baseline characteristics are summarized in Tables  1 and 2 . Except for differences in admission parasitemia and plasma bilirubin concentration, the treatment groups were well matched.
Lactate Clearance Time. Elevated admission plasma lactate concentrations (Ͼ2 mmol/L) were present in 99 of 108 patients (92%). Median lactate clearance time was 30 in the NAC treated and 42 hours in the placebo group (range, 6 -96 hours for NAC and 6 -144 hours for placebo, excluding expired patients). The Kaplan-Meier plot for lactate clearance time (Fig. 1a ), shows no difference between treatment groups (Wilcoxon-Breslow test, p ϭ 0.74), also after adjustment for ͓log͔ admission parasitemia and bilirubin (Hazard ratio: 0.98; 95% confidence interval ͓CI͔: 0.60 -1.62, p ϭ 0.95).
Coma Recovery Time. At admission 91 of 108 patients (84%) had impaired consciousness (GCS Ͻ15) of which 78 were in coma (72%) (GCS Ͻ11). Median coma recovery time was 72 hours in NACtreated patients and 96 hours in the placebo group (range 6 -120 hours in NAC and 6 -360 hours in the placebo group, excluding the patients who died). Kaplan-Meier analysis, where the coma recovery time for the fatal cases was regarded as infinite, showed no difference between treatment groups (Fig. 1b , Wilcoxon-Breslow test, p ϭ 0.46). Treatment had no effect on coma recovery time after adjustment for ͓log͔ admission parasitemia and bilirubin (Hazard ratio: 1.05; 95% CI: 0.58 -1.88, p ϭ 0.88). Parasite Clearance Time. Using Kaplan-Meier analysis (Fig. 1c ) parasite clearance was faster in patients receiving placebo (Wilcoxon-Breslow p ϭ 0.03). Parasite clearance time, censoring the fatal cases at the time of death, was 36 hours (range, 6 -120) in the NAC-treated patients and 30 hours (range, 6 -144) in the placebo group. However, admission parasitemias were significantly higher in the NAC-treated patients (geometric mean: 118,843 parasites/L ͓95% CI: 77,535-169,005͔), compared with 57,178 parasites/L (95% CI: 33,327-95,531) in the control group (p ϭ 0.021), and admission (log) parasitemia correlated with (log) parasite clearance time (r ϭ .67, p Ͻ 0.0005). In the Cox regression analysis, adjusting for ͓log͔ parasitemia and bilirubin levels at admission, treatment allocation (NAC or placebo) did not significantly affect parasite clearance time (Hazard ratio: 1.17; 95% CI: 0.74 -1.86, p ϭ 0.51).
Other parasite clearance measures also did not show any difference between treatment groups: mean median (range) PRR at 24 hours was 370 (1-infinite) in the NAC group and 170 (1-infinite) in the placebo group ( p ϭ 0.56); PRR at 48 hours was 3316 (4-infinite) and 3140 (1infinite, p ϭ 0.94), respectively; the geometric mean time (95% CI) to 50% clearance of parasites (PC50) was 8.1 hours (6.31-10.42) in the NAC group and 6.6 hours (5. 13-8.38) in the placebo group (p ϭ 0.23); for PC90, times were 19.1 hours (15.57-23.53) and 18.6 hours (15.88 -21.87, p ϭ 0.84), respectively. Thus, there was no evidence that NAC prolonged parasite clearance by artesunate.
Fever Clearance Time. There was no difference in fever clearance times between the two treatment groups by Kaplan-Meier analysis (Wilcoxon-Breslow, p ϭ 0.49). Fever clearance time, censoring the fatal cases at the time of death, was 24 hours for both treatment groups (range, 6 -96 hours for the NAC and 6 -360 hrs in the placebo group) and adjustment for ͓log͔ parasitemia at admission and bilirubin in the Cox model did not change this result (Hazard ratio: 0.81; 95% CI: 0.43-1.53, p ϭ 0.52).
Mortality. The overall mortality in this severely ill group of patients was 35% (38 of 108 patients, Table 3 ), with 21 fatal cases (38%) in the NAC group vs. 17 in the placebo group (33%), which was not significantly different by survival analysis (Wilcoxon-Breslow, p ϭ 0.52). The level of supportive and intensive care unit care was higher in Mae Sot General Hospital in Thailand, and mortality was significantly lower at this study site (9% vs. 42%, p ϭ 0.003). Median time to death was 16 hours in both the NAC and placebo-treated groups (range 2-204 hours in the NAC group and 3-288 in the placebo group). In a multiple logistic regression analysis with mortality as the dependent variable, allocation to NAC or placebo did not contribute to the model in addition to the presenting severity symptoms.
Red Cell Deformability. Admission red cell deformability at a shear stress of 1.7 Pa (as mean elongation index, 95% CI) was assessed in 87 patients. Red cell deformability was lower in fatal cases: 0.182 (0.169 -0.194), compared with 0.198 (0.189 -0.207) in patients who survived (p ϭ 0.03). There was no significant change in red cell deformability in the first 24 hours after admission in either group: mean change (95% CI) 3.1% (Ϫ6.5% to 12.8%) in the NAC-treated group (p ϭ 0.50) and 3.1% (Ϫ6.1% to 12.3%) in the placebo group (p ϭ 0.49).
Measures of Oxidative Stress. Urine F 2 -isoP-M concentrations were assessed in 50 of the patients with severe malaria. For comparison, these were also assessed in 15 local volunteers, 13 patients with uncomplicated falciparum malaria, and 4 patients with Plasmodium vivax infection. After correction for renal function, geometric mean urine F 2 -isoP-M were significantly higher in patients with severe malaria compared with uncomplicated malaria, P. vivax, and healthy controls (Fig. 2) ; the corrected geometric mean F 2 -isoP-M concentrations (95% CI, p of difference with value in severe malaria) were 556 pg/mL CrCl (392-787) for patients with severe malaria; for uncomplicated falciparum malaria 183 pg/mL CrCl (114 -293, p ϭ 0.002); in vivax malaria 139 pg/mL CrCl (23-825, p ϭ 0.02), and in healthy controls 176 pg/mL CrCl (89 -350, p ϭ 0.002). Within the group of patients with severe malaria, there was no difference (p ϭ 0.44) in corrected urinary F 2 -isoP-M concentrations at admission between survivors and fatal cases: geometric mean (95% CI) 613 pg/mL CrCl (384 -979) in survivors (n ϭ 33) and 460 pg/mL CrCl (271-779) in fatal cases (n ϭ 17). There was no significant correlation with admission hemoglobin, red cell deformability, or lactate concentrations. In 32 severe malaria patients, longitudinal data at 24 hours were available. No change in urinary F 2 -isoP-M concentrations (corrected for renal function) were observed in the 15 patients treated with NAC (F 2 -isoP-M: mean percent change, 95% CI ϭ 2.7%, Ϫ8.7 to 14.2, p ϭ 0.62), nor in the 17 patients treated with placebo (6.3%, Ϫ2.7 to 16.9, p ϭ 0.22).
Adverse Events. No adverse events related to NAC were observed, including allergic reactions. There was no difference in the proportion of patients presenting with severe complications upon admission between the NAC-treatment group and the placebo ( Table 3) .
DISCUSSION
This study evaluated the effects of NAC as an adjuvant to intravenous artesunate for the treatment of severe falciparum malaria. A smaller pilot study had shown previously that clearance of elevated plasma lactate levels and coma recovery times were accelerated by NAC (13) . Both parameters have strong prognostic significance in severe malaria. For both variables, there was no significant difference between NAC or placebo-treated patients in the present study. The main difference with the earlier pilot study was antimalarial treatment with artesunate rather than quinine. Since mortality is lower and parasite clearance times, and possibly lactate clearance times, shorter in patients treated with artesunate compared with quinine, an additional effect of NAC might be more difficult to demonstrate in the current study. Despite strict randomization, patients in the NAC groups had higher levels of parasitemia and bilirubin at admission. However, the results from the Kaplan-Meier analyses were consistent with the results from multivariate analyses, which were controlled for admission parasitemia and bilirubin levels, thereby taking the differences into account.
Mortality, fever clearance time, and complications or adverse events also did not differ between treatment groups. We have recently shown that the antiplasmodial action of artesunate is slightly antagonized by the antioxidant NAC (16) . This inhibitory effect was no longer observed when the NAC was added 2 hours after incubation with artesunate. In the current study, NAC was started 2 hours after artesunate administration. Although parasite clearance times were significantly longer in the NAC treatment group in the univariate analysis, when adjusted for admission parasitemia and bilirubin levels, treatment allocation did not have a significant effect on parasite clearance time. Furthermore, other measures of parasite clearance, which are less dependent on the admission parasitemia, such as the PRR, were not different between treatment groups. Fever clearance times were also not different between the study groups. This argues against a major antagonistic effect of NAC on the antimalarial activity of artesunate in vivo. An earlier study in children with severe malaria described an association between an increase in reactive oxygen intermediate production measured by luminol-enhanced chemiluminescence, and severity of disease, especially severe anemia (2) . Severe malarial anemia has been linked to oxidative damage of the red cell membrane (9) . In our study, urine concentrations of F 2 -isoP-M were significantly increased in patients with severe malaria, compared with patients with uncomplicated malaria, vivax malaria, and healthy controls from the same ethnic background. Treatment with an artemisinin, which has oxidative properties, could have contributed to the urinary reactive oxygen intermediates in patients with severe malaria and uncomplicated falciparum malaria, in contrast to those with vivax malaria, who were treated with chloroquine, or healthy controls. We did not observe a correlation with severity of anemia. Recently, it has been shown that plasma L-arginine levels are reduced in severe malaria and that this is associated with decreased nitric oxide production by nitric oxide synthase (26) . With low L-arginine levels, nitric oxide synthase generates superoxide rather than nitric oxide, which can add to the increase in oxidative stress in severe malaria. Measurement of F 2 -isoprostanes metabolites in the urine has emerged as a reliable noninvasive method to determine systemic levels of oxidative stress in vivo (27) .
Although our study affirms that oxidative stress is increased in severe malaria, intervention with high-dose NAC did not show any measurable effect. Labile prostaglandin H 2 -like endoperoxides (H 2isoprostanes) are intermediates in the formation of F 2 -isoprostanes. H 2 -isoprostanes are reduced to form F 2 -isoprostanes, but can undergo rearrangement in vivo to form E-ring and D-ring isoprostanes. Since reduction to F 2 -isoprostanes is catalyzed by thiols (28) , NAC could increase the ratio between F 2 -isoprostanes and E2/D2 isoprostanes, obscuring its antioxidative effect.
The current study reinforces the prognostic significance of red cell rigidity, as previously shown in both adult and pediatric severe malaria (8, 29) . Oxidative damage to the red cell membrane has been proposed as a cause for decreased red cell deformability (7) , but in our study deformability did not correlate with urinary F 2 -isoprostanes concentrations and was not restored by NAC.
In addition to its antioxidative properties (30) , additional beneficial effects of NAC have been described in septic shock, such as a vasodilatory effect (10, (31) (32) (33) , associated with a reduction in serum lactate concentrations (34, 35) , as well as a reduction in nuclear factor kappa-B (36), tumor necrosis factor (34) , and interleukin-8 levels (36, 37) with reduced expression of endothelial receptors vascular cell adhesion molecule-1 and endothelial leukocyte adhesion molecule. However, some of these findings were not reproduced in other studies (38, 39) . Vasodilatory effects might be less relevant in severe malaria, where microcirculatory hypoperfusion is mainly determined by the mechanical obstruction resulting from sequestration of parasitized red blood cells (8) . In patients with severe malaria, no changes in plasma concentrations of tumor necrosis factor-␣, interleukin-6, interleukin-8, or interferongamma could be demonstrated with high-dose NAC treatment (13) . In the mouse model, antioxidants other than NAC have been shown to reduce mortality (40) , and different antioxidant substances vary in their effect on immune function (41) . It cannot, therefore, be excluded that other antioxidants might have a beneficial effect in human patients. However, the pathogenesis of cerebral malaria in mice is quite distinct from the disease in humans.
In conclusion, this study showed that although measures of oxidative stress were increased in severe malaria, no beneficial effects from the use of high-dose NAC as an adjunctive treatment to intravenous artesunate could be observed in the setting of the study.
